Is Ultragenyx (RARE) overvalued? · rev $350.0M
Ultragenyx (RARE) is a biotechnology company listed on US.
This page asks whether Ultragenyx (RARE) looks expensive on cached numbers — not a short thesis.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
RARE currently screens at market cap $2.79B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RARE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RARE stock page for the full model, not this heading.
Not investment advice.